The diagnostic accuracy and costeffectiveness of magnetic resonance spectroscopy and enhanced magnetic resonance imaging techniques in aiding the localisation of prostate abnormalities for biopsy: A systematic review and economic evaluation

Health Technology Assessment

Volumn 17, Issue 20, 2013, Pages

  Mowatt, G ^a   Scotland, G ^a,b   Boachie, C ^a   Cruickshank, M ^a   Ford, J A ^a   Fraser, C ^a   Kurban, L ^c   Lam, T B ^b   Padhani, A R ^d   Royle, J ^c   Scheenen, T W ^e   Tassie, E ^b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^d MOUNT VERNON CANCER CENTRE   (United Kingdom)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSION WEIGHTED IMAGING; DYNAMIC CONTRAST ENHANCED NUCLEAR MAGNETIC RESONANCE IMAGING; HEALTH CARE COST; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE GUIDED BIOPSY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE DISEASE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; TRANSRECTAL ULTRASONOGRAPHY; BIOPSY; COST BENEFIT ANALYSIS; ECONOMICS; PATHOLOGY; PROCEDURES; PROSTATE; PROSTATIC NEOPLASMS; METHODOLOGY; PROSTATE TUMOR; REVIEW;

BIOPSY; COST-BENEFIT ANALYSIS; DIFFUSION MAGNETIC RESONANCE IMAGING; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PROSTATE; PROSTATIC NEOPLASMS;

EID: 84878488449     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta17200     Document Type: Article

References (182)

1. Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM. Complications after prostate biopsy: data from SEER-Medicare. J Urol 2011;186:1830-4. http://dx.doi.org/10.1016/j.juro.2011.06.057
2. Stewart CS, Leibovich BC, Weaver AL, Lieber MM. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol 2001;166:86-91. http://dx.doi.org/10.1016/S0022-5347(05)66083-1
3. Muruve NA. Prostate anatomy. New York, NY: Medscape; 2011. URL: http://emedicine.medscape. com/article/1923122-overview#aw2aab6b3 (accessed February 2013).
4. McNeal JE, Redwine EA, Freiha FS, Stamey TA. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol 1988;12:897-906. http://dx.doi.org/10.1097/00000478-198812000-00001
5. McNeal JE. Normal histology of the prostate. Am J Surg Pathol 1988;12:619-33. http://dx.doi. org/10.1097/00000478-198808000-00003
6. American Cancer Society. Cancer facts and figures for African Americans 2009-2010. Atlanta, GA: American Cancer Society; 2010. URL: www.cancer.org/docroot/STT/content/STT_1x_Cancer_Facts_Figures_for_Afric an_Americans_2009-2010_09.asp (accessed June 2012).
7. Cancer Research UK. Prostate cancer-UK incidence statistics 2009. London: Cancer Research UK; 2009. URL: http://info.cancerresearchuk.org/cancerstats/types/prostate/incidence (accessed June 2012).
8. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300. http://dx.doi.org/10.3322/caac.20073
9. National Institute for Health and Care Excellence (NICE). NICE CG58 prostate cancer: full guidance. London: NICE; 2008. URL: http://guidance.nice.org.uk/CG58/Guidance/pdf/English (accessed June 2012).
10. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997;277:1445-51. http://dx.doi.org/10.1001/jama.1997.03540420041027
11. Spigelman SS, McNeal JE, Freiha FS, Stamey TA. Rectal examination in volume determination of carcinoma of the prostate: clinical and anatomical correlations. J Urol 1986;136:1228-30.
12. Futterer JJ, Heijmink SW, Scheenen TW, Jager GJ, Hulsbergen-van de Kaa CA, Witjes JA, et al. Prostate cancer: local staging at 3-T endorectal MR imaging-early experience. Radiology 2006;238:184-91. http://dx.doi.org/10.1148/radiol.2381041832
13. Katz DA, Jarrard DF, McHorney CA, Hillis SL, Wiebe DA, Fryback DG. Health perceptions in patients who undergo screening and workup for prostate cancer. Urology 2007;69:215-20. http://dx.doi. org/10.1016/j.urology.2006.09.059
14. Kirby R, Fitzpatrick JM. Optimising repeat prostate biopsy decisions and procedures. BJU Int 2012;109:1750-4. http://dx.doi.org/10.1111/j.1464-410X.2011.10809.x
15. McGovern PM, Gross CR, Krueger RA, Engelhard DA, Cordes JE, Church TR. False-positive cancer screens and health-related quality of life. Cancer Nurs 2004;27:347-52. http://dx.doi. org/10.1097/00002820-200409000-00003
16. Johansson JE, Andren O, Andersson SO, Dickman PW, Holmberg L, Magnuson A, et al. Natural history of early, localized prostate cancer. JAMA 2004;291:2713-19. http://dx.doi.org/10.1001/jama.291.22.2713
17. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011;59:61-71. http://dx.doi.org/10.1016/j.eururo.2010.10.039
18. Wefer AE, Hricak H, Vigneron DB, Coakley FV, Lu Y, Wefer J, et al. Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol 2000;164:400-4. http://dx.doi. org/10.1016/S0022-5347(05)67370-3
19. Chybowski FM, Keller JJ, Bergstralh EJ, Oesterling JE. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J Urol 1991;145:313-18.
20. Rana A, Karamanis K, Lucas MG, Chisholm GD. Identification of metastatic disease by T category, Gleason score and serum PSA level in patients with carcinoma of the prostate. Br J Urol 1992;69:277-81. http://dx.doi.org/10.1111/j.1464-410X.1992.tb15528.x
21. Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ Jr, Dotan ZA, Fearn PA, et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 2006;98:715-17. http://dx.doi.org/10.1093/jnci/djj190
22. Bruwer G, Heyns CF, Allen FJ. Influence of local tumour stage and grade on reliability of serum prostate-specific antigen in predicting skeletal metastases in patients with adenocarcinoma of the prostate. Eur Urol 1999;35:223-7. http://dx.doi.org/10.1159/000019850
23. Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 7th edn. Oxford: Wiley-Blackwell; 2009.
24. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974;111:58-64.
25. Gleason DF. The Veterans' Administration Cooperative Urologic Research Group: histologic grading and clinical staging of prostatic carcinoma. In Tannenbaum M, editor. Urologic pathology: the prostate. Philadelphia, PA: Lea and Febiger; 1977. pp. 171-97.
26. Epstein JI. Gleason score 2-4 adenocarcinoma of the prostate on needle biopsy: a diagnosis that should not be made. Am J Surg Pathol 2000;24:477-8. http://dx.doi. org/10.1097/00000478-200004000-00001
27. Kattan MW, Zelefsky MJ, Kupelian PA, Scardino PT, Fuks Z, Leibel SA. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 2000;18:3352-9.
28. Kattan MW, Potters L, Blasko JC, Beyer DC, Fearn P, Cavanagh W, et al. Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology 2001;58:393-9. http://dx.doi.org/10.1016/S0090-4295(01)01233-X
29. D'Amico AV, Whittington R, Malkowicz SB, Fondurulia J, Chen MH, Kaplan I, et al. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol 1999;17:168-72.
30. Makarov DV, Trock BJ, Humphreys EB, Mangold LA, Walsh PC, Epstein JI, et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 2007;69:1095-101. http://dx.doi.org/10.1016/j.urology.2007.03.042
31. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-74. http://dx.doi.org/10.1001/jama.280.11.969
32. Fuchsjager MH, Shukla-Dave A, Hricak H, Wang L, Touijer K, Donohue JF, et al. Magnetic resonance imaging in the prediction of biochemical recurrence of prostate cancer after radical prostatectomy. BJU Int 2009;104:315-20. http://dx.doi.org/10.1111/j.1464-410X.2009.08406.x
33. Shukla-Dave A, Hricak H, Akin O, Yu C, Zakian KL, Udo K, et al. Preoperative nomograms incorporating magnetic resonance imaging and spectroscopy for prediction of insignificant prostate cancer. BJU Int 2012;109:1315-22. http://dx.doi.org/10.1111/j.1464-410X.2011.10612.x
34. Wang L, Hricak H, Kattan MW, Chen HN, Scardino PT, Kuroiwa K. Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms. Radiology 2006;238:597-603. http://dx.doi.org/10.1148/radiol.2382041905
35. Nguyen CT, Jones JS. Focal therapy in the management of localized prostate cancer. BJU Int 2011;107:1362-8. http://dx.doi.org/10.1111/j.1464-410X.2010.09975.x
36. US Department of Health and Human Services: Agency for Healthcare Research and Quality (AHRQ). Comparative effectiveness of therapies for clinically localized prostate cancer: health care bulletin no. 13. Rockville, MD, USA: AHRQ; 2008. URL: http://effectivehealthcare.ahrq.gov/index.cfm/searchfor-guides-reviews-a nd-reports/?pageaction=displayproduct&productid=79 (accessed June 2012).
37. Campos-Fernandes JL, Bastien L, Nicolaiew N, Robert G, Terry S, Vacherot F, et al. Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy. Eur Urol 2009;55:600-6. http://dx.doi.org/10.1016/j.eururo.2008.06.043
38. Scattoni V, Raber M, Capitanio U, Abdollah F, Roscigno M, Angiolilli D, et al. The optimal rebiopsy prostatic scheme depends on patient clinical characteristics: results of a recursive partitioning analysis based on a 24-core systematic scheme. Eur Urol 2011;60:834-41. http://dx.doi. org/10.1016/j.eururo.2011.07.036
39. National Institute for Health and Care Excellence (NICE). Prostate cancer (metastatic, castration resistant)-abiraterone (following cytoxic therapy): final appraisal determination guidance. London: NICE; 2012. URL: http://guidance.nice.org.uk/TA/Wave26/4/FAD/FinalAppraisalDetermination/ pdf/English (accessed June 2012).
40. Zaytoun OM, Jones JS. Prostate cancer detection after a negative prostate biopsy: lessons learnt in the Cleveland Clinic experience. Int J Urol 2011;18:557-68. http://dx.doi. org/10.1111/j.1442-2042.2011.02798.x
41. Department of Health. NHS reference costs 2009-10. London: Department of Health; 2011. URL: www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPoli cyAndGuidance/DH_123459 (accessed June 2012).
42. Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G, et al. ESUR prostate MR guidelines 2012. Eur Radiol 2012;22:746-57. http://dx.doi.org/10.1007/s00330-011-2377-y
43. The Royal College of Radiologists. iREFER guidelines. London: Royal College of Radiologists; 2012. URL: www.irefer.org.uk (accessed June 2012).
44. The Royal College of Radiologists. CASPAR-The Cancer Staging Proforma Reporting Project. London: Royal College of Radiologists; 2012. URL: www.rcr.ac.uk (accessed June 2012).
45. Kurhanewicz J, Vigneron DB, Hricak H, Narayan P, Carroll P, Nelson SJ. Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. Radiology 1996;198:795-805.
46. Scheenen TW, Klomp DW, Roll SA, Futterer JJ, Barentsz JO, Heerschap A. Fast acquisition-weighted three-dimensional proton MR spectroscopic imaging of the human prostate. Magn Reson Med 2004;52:80-8. http://dx.doi.org/10.1002/mrm.20103
47. Verma S, Rajesh A, Futterer JJ, Turkbey B, Scheenen TW, Pang Y, et al. Prostate MRI and 3D MR spectroscopy: how we do it. AJR Am J Roentgenol 2010;194:1414-26. http://dx.doi.org/10.2214/AJR.10.4312
48. Klijn S, De Visschere PJ, De Meerleer GO, Villeirs GM. Comparison of qualitative and quantitative approach to prostate MR spectroscopy in peripheral zone cancer detection. Eur J Radiol 2012;81:411-16. http://dx.doi.org/10.1016/j.ejrad.2010.12.017
49. Scheenen TW, Futterer J, Weiland E, van Hecke P, Lemort M, Zechmann C, et al. Discriminating cancer from noncancer tissue in the prostate by 3-dimensional proton magnetic resonance spectroscopic imaging: a prospective multicenter validation study. Invest Radiol 2011;46:25-33. http://dx.doi.org/10.1097/RLI.0b013e3181f54081
50. Futterer JJ, Scheenen TW, Heijmink SW, Huisman HJ, Hulsbergen-van de Kaa CA, Witjes JA, et al. Standardized threshold approach using three-dimensional proton magnetic resonance spectroscopic imaging in prostate cancer localization of the entire prostate. Invest Radiol 2007;42:116-22. http://dx.doi.org/10.1097/01.rli.0000251541.03822.bb
51. Jung JA, Coakley FV, Vigneron DB, Swanson MG, Qayyum A, Weinberg V, et al. Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system. Radiology 2004;233:701-8. http://dx.doi.org/10.1148/radiol.2333030672
52. Kobus T, Hambrock T, Hulsbergen-van de Kaa CA, Wright AJ, Barentsz JO, Heerschap A, et al. In vivo assessment of prostate cancer aggressiveness using magnetic resonance spectroscopic imaging at 3T with an endorectal coil. Eur Urol 2011;60:1074-80. http://dx.doi.org/10.1016/j. eururo.2011.03.002
53. Scheidler J, Hricak H, Vigneron DB, Yu KK, Sokolov DL, Huang LR, et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging-clinicopathologic study. Radiology 1999;213:473-80.
54. Zakian KL, Sircar K, Hricak H, Chen HN, Shukla-Dave A, Eberhardt S, et al. Correlation of proton MR spectroscopic imaging with Gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology 2005;234:804-14. http://dx.doi.org/10.1148/radiol.2343040363
55. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999;10:223-32. http://dx.doi.org/10.1002/(SICI)1522-2586(199909)10:3(223::AID-JMRI223.0 .CO;2-S
56. Leach MO, Morgan B, Tofts PS, Buckley DL, Huang W, Horsfield MA, et al. Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging. Eur Radiol 2012;22:1451-64. http://dx.doi.org/10.1007/s00330-012-2446-x
57. Beyersdorff D, Taupitz M, Winkelmann B, Fischer T, Lenk S, Loening SA, et al. Patients with a history of elevated prostate-specific antigen levels and negative transrectal US-guided quadrant or sextant biopsy results: value of MR imaging. Radiology 2002;224:701-6. http://dx.doi.org/10.1148/radiol.2243011553
58. Futterer JJ, Heijmink SW, Scheenen TW, Veltman J, Huisman HJ, Vos P, et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 2006;241:449-58. http://dx.doi.org/10.1148/radiol.2412051866
59. Hara N, Okuizumi M, Koike H, Kawaguchi M, Bilim V. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a useful modality for the precise detection and staging of early prostate cancer. Prostate 2005;62:140-7. http://dx.doi.org/10.1002/pros.20124
60. Cirillo S, Petracchini M, Scotti L, Gallo T, Macera A, Bona MC, et al. Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging. Eur Radiol 2009;19:761-9. http://dx.doi.org/10.1007/s00330-008-1174-8
61. Haider MA, Chung P, Sweet J, Toi A, Jhaveri K, Menard C, et al. Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys 2008;70:425-30. http://dx.doi.org/10.1016/j. ijrobp.2007.06.029
62. Turkbey B, Shah VP, Pang Y, Bernardo M, Xu S, Kruecker J, et al. Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images? Radiology 2011;258:488-95. http://dx.doi.org/10.1148/radiol.10100667
63. van As NJ, de Souza NM, Riches SF, Morgan VA, Sohaib SA, Dearnaley DP, et al. A study of diffusion-weighted magnetic resonance imaging in men with untreated localised prostate cancer on active surveillance. Eur Urol 2009;56:981-7. http://dx.doi.org/10.1016/j.eururo.2008.11.051
64. Hambrock T, Somford DM, Huisman HJ, Van Oort IM, Witjes JA, Hulsbergen-van de Kaa CA, et al. Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology 2011;259:453-61. http://dx.doi.org/10.1148/radiol.11091409
65. Oto A, Kayhan A, Jiang Y, Tretiakova M, Yang C, Antic T, et al. Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging. Radiology 2010;257:715-23. http://dx.doi.org/10.1148/radiol.10100021
66. Villeirs GM, De Meerleer GO, De Visschere PJ, Fonteyne VH, Verbaeys AC, Oosterlinck W. Combined magnetic resonance imaging and spectroscopy in the assessment of high grade prostate carcinoma in patients with elevated PSA: a single-institution experience of 356 patients. Eur J Radiol 2011;77:340-5. http://dx.doi.org/10.1016/j.ejrad.2009.08.007
67. Villers A, Puech P, Mouton D, Leroy X, Ballereau C, Lemaitre L. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. J Urol 2006;176:2432-7. http://dx.doi. org/10.1016/j.juro.2006.08.007
68. Ellis WJ, Chetner MP, Preston SD, Brawer MK. Diagnosis of prostatic carcinoma: the yield of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography. J Urol 1994;152:1520-5.
69. Lee F, Torp-Pedersen ST, Siders DB, Littrup PJ, McLeary RD. Transrectal ultrasound in the diagnosis and staging of prostatic carcinoma. Radiology 1989;170:1-15.
70. Umbehr M, Bachmann LM, Held U, Kessler TM, Sulser T, Weishaupt D, et al. Combined magnetic resonance imaging and magnetic resonance spectroscopy imaging in the diagnosis of prostate cancer: a systematic review and meta-analysis. Eur Urol 2009;55:575-90. http://dx.doi. org/10.1016/j.eururo.2008.10.019
71. Eskew LA, Bare RL, McCullough DL. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 1997;157:199-202. http://dx.doi. org/10.1016/S0022-5347(01)65322-9
72. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003;3:25. http://dx.doi.org/10.1186/1471-2288-3-25
73. Takwoingi Y. METADAS: diagnostic test accuracy meta-analysis-bivariate and HSROC model. Cochrane Collaboration Diagnostic Test Accuracy Group; 2008. URL: http://srdta.cochrane.org/software-development (accessed June 2012).
74. Amsellem-Ouazana D, Younes P, Conquy S, Peyromaure M, Flam T, Debre B, et al. Negative prostatic biopsies in patients with a high risk of prostate cancer. Is the combination of endorectal MRI and magnetic resonance spectroscopy imaging (MRSI) a useful tool? A preliminary study. Eur Urol 2005;47:582-6. http://dx.doi.org/10.1016/j.eururo.2005.01.015
75. Babaian RJ, Toi A, Kamoi K, Troncoso P, Sweet J, Evans R, et al. A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. J Urol 2000;163:152-7. http://dx.doi. org/10.1016/S0022-5347(05)67993-1
76. Bhatia C, Phongkitkarun S, Booranapitaksonti D, Kochakarn W, Chaleumsanyakorn P. Diagnostic accuracy of MRI/MRSI for patients with persistently high PSA levels and negative TRUS-guided biopsy results. J Med Assoc Thai 2007;90:1391-9.
77. Campodonico F, Casarico A, Gavazzi L, Calcagno T, Capponi G, Canepa G, et al. Cancer detection with TRUS-guided 10-core biopsy of the prostate. An institutional assessment at the first, repeated and surgical specimen biopsy. Arch Ital Urol Androl 2006;78:39-43.
78. Cheikh AB, Girouin N, Colombel M, Marechal JM, Gelet A, Bissery A, et al. Evaluation of T2-weighted and dynamic contrast-enhanced MRI in localizing prostate cancer before repeat biopsy. Eur Radiol 2009;19:770-8. http://dx.doi.org/10.1007/s00330-008-1190-8
79. Cirillo S, Petracchini M, Della MP, Gallo T, Tartaglia V, Vestita E, et al. Value of endorectal MRI and MRS in patients with elevated prostate-specific antigen levels and previous negative biopsies to localize peripheral zone tumours. Clin Radiol 2008;63:871-9. http://dx.doi.org/10.1016/j. crad.2007.10.020
80. de la Rosette JJ, Wink MH, Mamoulakis C, Wondergem N, ten Kate FJ, Zwinderman K, et al. Optimizing prostate cancer detection: 8 versus 12-core biopsy protocol. J Urol 2009;182:1329-36. http://dx.doi.org/10.1016/j.juro.2009.06.037
81. Djavan B, Ravery V, Zlotta A, Dobronski P, Dobrovits M, Fakhari M, et al. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? J Urol 2001;166:1679-83. http://dx.doi.org/10.1016/S0022-5347(05)65652-2
82. Engelhard K, Hollenbach HP, Kiefer B, Winkel A, Goeb K, Engehausen D. Prostate biopsy in the supine position in a standard 1.5-T scanner under real time MR-imaging control using a MR-compatible endorectal biopsy device. Eur Radiol 2006;16:1237-43. http://dx.doi.org/10.1007/s00330-005-0100-6
83. Eskicorapci SY, Guliyev F, Islamoglu E, Ergen A, Ozen H. The effect of prior biopsy scheme on prostate cancer detection for repeat biopsy population: results of the 14-core prostate biopsy technique. Int Urol Nephrol 2007;39:189-95. http://dx.doi.org/10.1007/s11255-006-9009-5
84. Franiel T, Stephan C, Erbersdobler A, Dietz E, Maxeiner A, Hell N, et al. Areas suspicious for prostate cancer: MR-guided biopsy in patients with at least one transrectal US-guided biopsy with a negative finding-multiparametric MR imaging for detection and biopsy planning. Radiology 2011;259:162-72. http://dx.doi.org/10.1148/radiol.10101251
85. Hambrock T, Futterer JJ, Huisman HJ, Hulsbergen-van de Kaa C, van Basten JP, van Oort I, et al. Thirty-two-channel coil 3T magnetic resonance-guided biopsies of prostate tumor suspicious regions identified on multimodality 3T magnetic resonance imaging: technique and feasibility. Invest Radiol 2008;43:686-94. http://dx.doi.org/10.1097/RLI.0b013e31817d0506
86. Hambrock T, Somford DM, Hoeks C, Bouwense SA, Huisman H, Yakar D, et al. Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. J Urol 2010;183:520-7. http://dx.doi.org/10.1016/j.juro.2009.10.022
87. Hoeks CMA, Schouten MG, Bomers JGR, Hoogendoorn SP, Hulsbergen-van de Kaa CA, Hambrock T, et al. Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostatespecific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers. Eur Urol 2012;62:902-9. http://dx.doi. org/10.1016/j.eururo.2012.01.047
88. Keetch DW, Catalona WJ, Smith DS. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol 1994;151:1571-4.
89. Labanaris AP, Engelhard K, Zugor V, Nützel R, Kühn R. Prostate cancer detection using an extended prostate biopsy schema in combination with additional targeted cores from suspicious images in conventional and functional endorectal magnetic resonance imaging of the prostate. Prostate Cancer Prostatic Dis 2010;13:65-70. http://dx.doi.org/10.1038/pcan.2009.41
90. Lattouf JB, Grubb RL III, Lee SJ, Bjurlin MA, Albert P, Singh AK, et al. Magnetic resonance imagingdirected transrectal ultrasonography-guided biopsies in patients at risk of prostate cancer. BJU Int 2007;99:1041-6. http://dx.doi.org/10.1111/j.1464-410X.2006.06690.x
91. Lin CC, Huang WJ, Wu LJ, Chang YH, Lin AT, Chen KK. Diagnosis of prostate cancer: repeated transrectal prostate biopsy or transurethral resection. JCMA 2008;71:448-54.
92. Lopez-Corona E, Ohori M, Scardino PT, Reuter VE, Gonen M, Kattan MW. A nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative biopsy session. J Urol 2003;170:1184-8. http://dx.doi.org/10.1097/01.ju.0000087451.64657.fa
93. Ozden E, Turgut AT, Yaman O, Gulpinar O, Baltaci S. Follow-up of the transrectal ultrasonographic features of the prostate after biopsy: does any ultrasonographically detectable lesion form secondary to the first biopsy? J Ultrasound Med 2005;24:1659-63.
94. Panebianco V, Sciarra A, Ciccariello M, Lisi D, Bernardo S, Cattarino S, et al. Role of magnetic resonance spectroscopic imaging ([1H]MRSI) and dynamic contrast-enhanced MRI (DCE-MRI) in identifying prostate cancer foci in patients with negative biopsy and high levels of prostatespecific antigen (PSA). Radiol Med (Torino) 2010;115:1314-29. http://dx.doi.org/10.1007/s11547-010-0575-3
95. Panebianco V, Sciarra A, De Berardinis E, Busetto GM, Lisi D, Buonocore V, et al. PCA3 urinary test versus 1H-MRSI and DCEMR in the detection of prostate cancer foci in patients with biochemical alterations. Anticancer Res 2011;31:1399-405.
96. Park BK, Lee HM, Kim CK, Choi HY, Park JW. Lesion localization in patients with a previous negative transrectal ultrasound biopsy and persistently elevated prostate specific antigen level using diffusion-weighted imaging at three Tesla before rebiopsy. Invest Radiol 2008;43:789-93. http://dx.doi.org/10.1097/RLI.0b013e318183725e
97. Pepe P, Candiano G, Fraggetta F, Galia A, Grasso G, Aragona F. Is transition zone sampling at repeated saturation prostate biopsy still useful? Urol Int 2010;85:324-7. http://dx.doi. org/10.1159/000320108
98. Philip J, Hanchanale V, Foster CS, Javle P. Importance of peripheral biopsies in maximising the detection of early prostate cancer in repeat 12-core biopsy protocols. BJU Int 2006;98:559-62. http://dx.doi.org/10.1111/j.1464-410X.2006.06325.x
99. Pinsky PF, Crawford ED, Kramer BS, Andriole GL, Gelmann EP, Grubb R, et al. Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial. BJU Int 2007;99:775-9. http://dx.doi.org/10.1111/j.1464-410X.2007.06708.x
100. Portalez D, Rollin G, Leandri P, Elman B, Mouly P, Jonca F, et al. Prospective comparison of T2w-MRI and dynamic-contrast-enhanced MRI, 3D-MR spectroscopic imaging or diffusion-weighted MRI in repeat TRUS-guided biopsies. Eur Radiol 2010;20:2781-90. http://dx.doi.org/10.1007/s00330-010-1868-6
101. Prando A, Kurhanewicz J, Borges AP, Oliveira EM Jr, Figueiredo E. Prostatic biopsy directed with endorectal MR spectroscopic imaging findings in patients with elevated prostate specific antigen levels and prior negative biopsy findings: early experience. Radiology 2005;236:903-10. http://dx.doi.org/10.1148/radiol.2363040615
102. Quinlan MR, Casey RG, Flynn R, Grainger R, McDermott TE, Thornhill JA. A review of repeat prostate biopsies and the influence of technique on cancer detection: our experience. Ir J Med Sci 2009;178:287-90. http://dx.doi.org/10.1007/s11845-009-0362-0
103. Roehl KA, Antenor JA, Catalona WJ. Serial biopsy results in prostate cancer screening study. J Urol 2002;167:2435-9. http://dx.doi.org/10.1016/S0022-5347(05)64999-3
104. Roethke M, Anastasiadis AG, Lichy M, Werner M, Wagner P, Kruck S, et al. MRI-guided prostate biopsy detects clinically significant cancer: analysis of a cohort of 100 patients after previous negative TRUS biopsy. World J Urol 2012;30:213-18. http://dx.doi.org/10.1007/s00345-011-0675-2
105. Sciarra A, Panebianco V, Ciccariello M, Salciccia S, Cattarino S, Lisi D, et al. Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy. Clin Cancer Res 2010;16:1875-83. http://dx.doi. org/10.1158/1078-0432.CCR-09-2195
106. Testa C, Schiavina R, Lodi R, Salizzoni E, Tonon C, D'Errico A, et al. Accuracy of MRI/MRSI-based transrectal ultrasound biopsy in peripheral and transition zones of the prostate gland in patients with prior negative biopsy. NMR Biomed 2010;23:1017-26. http://dx.doi.org/10.1002/nbm.1522
107. Ukimura O, Durrani O, Joseph BR. Role of PSA and its indices in determining the need for repeat prostate biopsies. Urology 1997;50:66-72. http://dx.doi.org/10.1016/S0090-4295(97)00116-7
108. Wetter A, Hubner F, Lehnert T, Fliessbach K, Vorbuchner M, Roell S, et al. Three-dimensional 1H-magnetic resonance spectroscopy of the prostate in clinical practice: technique and results in patients with elevated prostate-specific antigen and negative or no previous prostate biopsies. Eur Radiol 2005;15:645-52. http://dx.doi.org/10.1007/s00330-004-2562-3
109. Yakar D, Schouten MG, Bosboom DG, Barentsz JO, Scheenen TW, Futterer JJ. Feasibility of a pneumatically actuated MR-compatible robot for transrectal prostate biopsy guidance. Radiology 2011;260:241-7. http://dx.doi.org/10.1148/radiol.11101106
110. Yanke BV, Salzhauer EW, Colon I. Is race a positive predictor of cancer on repeat prostate biopsy? J Urol 2006;176:1114-17. http://dx.doi.org/10.1016/j.juro.2006.04.041
111. Yuen JS, Lau WK, Ng LG, Tan PH, Khin LW, Cheng CW. Clinical, biochemical and pathological features of initial and repeat transrectal ultrasonography prostate biopsy positive patients. Int J Urol 2004;11:225-31. http://dx.doi.org/10.1111/j.1442-2042.2003.00772.x
112. Yuen JS, Thng CH, Tan PH, Khin LW, Phee SJ, Xiao D, et al. Endorectal magnetic resonance imaging and spectroscopy for the detection of tumor foci in men with prior negative transrectal ultrasound prostate biopsy. J Urol 2004;171:1482-6. http://dx.doi.org/10.1097/01.ju.0000118380.90871.ef
113. Zackrisson B, Aus G, Bergdahl S, Lilja H, Lodding P, Pihl CG, et al. The risk of finding focal cancer (less than 3 mm) remains high on re-biopsy of patients with persistently increased prostate specific antigen but the clinical significance is questionable. J Urol 2004;171:1500-3. http://dx.doi. org/10.1097/01.ju.0000118052.59597.83
114. Busetto GM, Panebianco V, Sciarra A, De Berardinis E, Tommaso B, Danilo L, et al. PCA3 urinary test versus 3T 1H-MRS and DCE-MRI in the detection of prostate cancer foci in patients with biochemical alterations. Anticancer Res 2011;31:1845.
115. Calvo N, Henriquez Lopez I, Pujol F, Milia L, Pont A, Grio J, et al. Utility of magnetic resonance spectroscopy and guided biopsies in patients with previous negative biopsies and suspicious of prostate cancer. Radiother Oncol 2010;96:S419.
116. Chung MS, Lee SH, Oh CK, Park SU, Rha KH, Oh YT, et al. MRI is important before repeat targeted biopsy in men with prior negative prostatic biopsy. Eur Urol 2010;9:501. http://dx.doi.org/10.1016/S1569-9056(10)61106-2
117. Comet-Batlle J, Vilanova-Busquets J, Maroto-Genover A, Bucar-Terrades S, Lopez-Bonet E, Barcelo-Obregon J, et al. Targeting prostate cancer in the central gland with endorectal MRI and spectroscopy. Eur Urol Suppl 2004;3:36. http://dx.doi.org/10.1016/S1569-9056(04)90137-6
118. Destefanis P, Bosio A, De Maria C, Bisconti A, Cugiani A, Negro CLA, et
119. Di Silverio F, Salciccia S, Busetto GM, Panebianco V, Sciarra A, Lisi D, et al. Is prostate biopsy still necessary? Anticancer Res 2011;31:1929-30.
120. Ghafoori M, Moradi M, Shakiba M, Hosseini K, Alavi M. Targeted TRUS guided biopsy of prostate with the aid of MR spectroscopy in patients with elevated PSA and negative previous systematic biopsy. J Med Imag Radiat 2010;54:A19.
121. Hambrock T, Somford D, Futterer J, Van Oort I, Van Basten J-P, Witjes A, et al. Value of 3 TESLA multi-modality directed MR guided biopsy to detect prostate cancer in patients after at least two previous negative biopsies and elevated PSA. J Urol 2009;181:706. http://dx.doi.org/10.1016/S0022-5347(09)61974-1
122. Hambrock T, Somford DM, Futterer JJ, Hoeks CMA, Hulsbergen-van de Kaa CA, Van Oort IM, et al. Value of 3 tesla multimodality MR guided biopsy (MRGB) to detect prostate cancer in patients after at least two previous negative biopsies and an elevated PSA. Eur Urol Suppl 2009;8:195. http://dx.doi.org/10.1016/S1569-9056(09)60303-1
123. Hambrock T, Somford DM, Hoeks H. Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. J Vasc Interv Radiol 2010;21:764.
124. Labanaris AP, Engelhard K, Smiszek R, Nützel R, Kühn R. Prostate cancer detection using an extended prostate biopsy schema in combination with additional targeted cores from suspicious images in conventional and functional endorectal magnetic resonance imaging of the prostate. J Urol 2009;181:711-12. http://dx.doi.org/10.1016/S0022-5347(09)61988-1
125. Labanaris AP, Engelhard K, Nützel R, Smiszek R, Kühn R. Endorectal magnetic resonance imaging of the prostate. A useful tool in the detection of anterior prostate cancer. J Urol 2010;183:e719. http://dx.doi.org/10.1016/j.juro.2010.02.1791
126. Lee SH, Yeom CD, Park KK, Chung MS, Chung BH, Rha KH. Hard to detect prostate cancer diagnosed by targeted biopsy using combined T2 weighted and diffusion weighted magnetic resonance imaging. J Urol 2011;185:e849-50. http://dx.doi.org/10.1016/j.juro.2011.02.2320
127. Perrotti M, Ankem MK, Weiss RE, Epstein R, Decarvalho VS, Kattan M, et al. Endorectal MRI: adjunct to repeat biopsy in prostate cancer detection. The smart biopsy. J Urol 2002;167:387.
128. Perrotti M, Shurtleff B, Rabbani F, Epstein R, Kennedy E, Weiss R, et al. Endorectal MRI-prospective localization of prostate tumor foci in men with prior negative prostatic biopsies: 60 consecutive cases. J Urol 2000;163:281. http://dx.doi.org/10.1016/S0022-5347(05)67589-1
129. Portalez D, Rollin G, Leandri P, Elman B, Mouly P, Jonca F, et al. Prospective comparison of T2w-MRI and dynamic-contrast-enhanced MRI, 3D-MR spectroscopic imaging or diffusion-weighted MRI in repeat TRUS-guided biopsies. Eur Urol Suppl 2010;9:197-8. http://dx.doi.org/10.1016/S1569-9056(10)60576-3
130. Rahman NU, Franks JH, Suhta A, Kurhanewicz J, Shinohara K. Utility of MRI/MRS in predicting prostate cancer for patients with multiple prior negative biopsies. J Urol 2003;169:495.
131. Sciarra A, Panebianco V, Salciccia S, Gentilucci A, Parente U, Alfarone A, et al. Value of magnetic resonance spectroscopy imaging (MRSI) and dynamic contrast-enhanced imaging MR (DCEMR) for the detection of prostate adenocarcinoma foci in men with prior negative prostate biopsy and elevated prostate specific antigen (PSA) levels. Eur Urol Suppl 2010;9:231. http://dx.doi. org/10.1016/S1569-9056(10)60693-8
132. Sciarra A, Panebianco V, Salciccia S, Alessandro G, Ulderico P, Andrea A, et al. Value of magnetic resonance spectroscopy imaging (MRSI) and dynamic contrast-enhanced imaging MR (DCEMR) for the detection of prostate adenocarcinoma foci in men with prior negative prostate biopsy and elevated prostate specific antigen (PSA) levels. J Urol 2010;183:e719. http://dx.doi.org/10.1016/j. juro.2010.02.1790
133. Valentini AL, Pinto F, Totaro A, Sacco E, Volpe A, Racioppi M, et al. Dynamic contrast-enhanced and diffusion-weighted magnetic resonance imaging and prostate cancer detection: preliminary results. Anticancer Res 2010;30:1500.
134. Wefer AE, Hricak H, Okuno W, Carroll P, Kurhanewicz J. Magnetic resonance imaging and spectroscopy: targeted prostate biopsy. J Urol 2000;163:280-1.
135. Winkelmann B, Beyersdorff D, Taupitz M, Deger S, Tuerk I, Loening SA. Value of high-resolution MR-imaging in patients with elevated PSA levels and negative TRUS-guided quadrant or sextant biopsy. J Urol 2001;165:317.
136. Yao DF, DeWolf WC, Sanda MG, Bloch BN, Genega EM, Berry AM, et al. Increased positive yield of clinically significant prostate cancer with MRI prompted biopsies. J Urol 2009;181:782-3. http://dx.doi.org/10.1016/S0022-5347(09)62179-0
137. Younes P, Zerbib M, Saighi D, Conquy S, Thiounn N, Flam T, et al. Interest of endorectal MRI for patients with a high risk of prostate cancer but negative sextant biopsies. Eur Urol 2001;39:148.
138. Stadlbauer A, Bernt R, Salomonowitz E, Plas E, Strunk G, Eberhardt K. [Health-economic evaluation of magnetic resonance imaging before biopsy for diagnosis of prostate cancer.] Rofo 2011;183:925-32. http://dx.doi.org/10.1055/s-0031-1281601
139. Hummel S, Simpson EL, Hemingway P, Stevenson MD, Rees A. Intensity-modulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation. Health Technol Assess 2010;14(47).
140. Calvert NW, Morgan AB, Catto JW, Hamdy FC, Akehurst RL, Mouncey P, et al. Effectiveness and cost-effectiveness of prognostic markers in prostate cancer. Br J Cancer 2003;88:31-5. http://dx.doi. org/10.1038/sj.bjc.6600630
141. Parker C, Muston D, Melia J, Moss S, Dearnaley D. A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. Br J Cancer 2006;94:1361-8. http://dx.doi.org/10.1038/sj.bjc.6603105
142. Etzioni R, Gulati R, Falcon S, Penson DF. Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach. Med Decis Making 2008;28:323-31. http://dx.doi.org/10.1177/0272989X07312719
143. Cowen ME, Chartrand M, Weitzel WF. A Markov model of the natural history of prostate cancer. J Clin Epidemiol 1994;47:3-21. http://dx.doi.org/10.1016/0895-4356(94)90029-9
144. Ramsay C, Pickard R, Robertson C, Close A, Vale L, Armstrong N, et al. Systematic review and economic modelling of the relative clinical benefit and cost-effectiveness of laparoscopic surgery and robotic surgery for removal of the prostate in men with localised prostate cancer. Health Technol Assess 2012;16(41).
145. Zhang J, Denton BT, Balasubramanian H, Shah ND, Inman BA. Optimization of PSA screening policies: a comparison of the patient and societal perspectives. Med Decis Making 2012;32:337-49. http://dx.doi.org/10.1177/0272989X11416513
146. Hegarty J, Beirne PV, Walsh E, Comber H, Fitzgerald T, Wallace KM. Radical prostatectomy versus watchful waiting for prostate cancer. Cochrane Database Syst Rev 2010;11:CD006590.
147. Iversen P, Madsen PO, Corle DK. Radical prostatectomy versus expectant treatment for early carcinoma of the prostate. Twenty-three year follow-up of a prospective randomized study. Scand J Urol Nephrol Suppl 1995;172:65-72.
148. Bill-Axelson A, Holmberg L, Ruutu M, Haggman M, Andersson SO, Bratell S, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011;364:1708-17. http://dx.doi.org/10.1056/NEJMoa1011967
149. Wilt TJ. VA/NCI/AHRQ Cooperative Studies Program #407: Prostate cancer Intervention Versus Observation Trial (PIVOT): main results from a randomized trial comparing radical prostatectomy to watchful waiting in men with clinically localized prostate cancer. American Urological Association; 2011. URL: http://webcasts.prous.com/AUA2011/html/1-en/CMEExam.aspx?section=16& lid=1810 8&eid=802 (accessed June 2012).
150. Rosario DJ, Lane JA, Metcalfe C, Donovan JL, Doble A, Goodwin L, et al. Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study. BMJ 2012;344:d7894. http://dx.doi.org/10.1136/bmj.d7894
151. Nam RK, Saskin R, Lee Y, Liu Y, Law C, Klotz LH, et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 2010;183:963-8. http://dx.doi.org/10.1016/j.juro.2009.11.043
152. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002;360:103-6. http://dx.doi. org/10.1016/S0140-6736(02)09408-4
153. Tappenden P, Chilcott J, Ward S, Eggington S, Hind D, Hummel S. Methodological issues in the economic analysis of cancer treatments. Eur J Cancer 2006;42:2867-75. http://dx.doi. org/10.1016/j.ejca.2006.08.010
154. Albertsen PC, Hanley JA, Penson DF, Barrows G, Fine J. 13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort. J Urol 2007;177:932-6. http://dx.doi.org/10.1016/j.juro.2006.10.051
155. South West Public Health Observatory (SWPHO). SWPHO Briefing 4: Prostate cancer survival by stage. Bristol: SWPHO; 2008. URL: www.swpho.nhs.uk/resource/item.aspx?RID=41287 (accessed June 2012).
156. Office for National Statistics (ONS). Life expectancy at birth, UK, 1980-82 to 2008-2010, UK interim life tables. London: ONS; 2012. URL: www.ons.gov.uk/ons/rel/lifetables/interim-lifetables/2008-2010/sum-ilt-2 008-10.html (accessed June 2012).
157. Curtis L. Unit costs of health and social care. Canterbury: Personal Social Services Research Unit; 2010. URL: www.pssru.ac.uk/pdf/uc/uc2010/uc2010.pdf (accessed June 2012).
158. British Medical Association and Royal Pharmaceutical Society of Great Britain. British national formulary. No. 63, March 2012. London: BMA and RPS; 2012.
159. Sacco E, Prayer-Galetti T, Pinto F, Fracalanza S, Betto G, Pagano F, et al. Urinary incontinence after radical prostatectomy: incidence by definition, risk factors and temporal trend in a large series with a long-term follow-up. BJU Int 2006;97:1234-41. http://dx.doi. org/10.1111/j.1464-410X.2006.06185.x
160. Stanford JL, Feng Z, Hamilton AS, Gilliland FD, Stephenson RA, Eley JW, et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA 2000;283:354-60. http://dx.doi.org/10.1001/jama.283.3.354
161. Ataman F, Zurlo A, Artignan X, van Tienhoven G, Blank LE, Warde P, et al. Late toxicity following conventional radiotherapy for prostate cancer: analysis of the EORTC trial 22863. Eur J Cancer 2004;40:1674-81. http://dx.doi.org/10.1016/j.ejca.2003.12.027
162. Heidenreich A, Bolla M, Joniau S, Mason MD, Matveev V, Mottet M, et al. Guidelines on benign prostate cancer. Arnhem, The Netherlands: European Association of Urology; 2012. URL: www. uroweb.org/gls/pdf/08%20Prostate%20Cancer_LR%20March%2013th%202012.pdf (accessed June 2012).
163. Korfage IJ, Essink-Bot ML, Borsboom GJ, Madalinska JB, Kirkels WJ, Habbema JD, et al. Five-year follow-up of health-related quality of life after primary treatment of localized prostate cancer. Int J Cancer 2005;116:291-6. http://dx.doi.org/10.1002/ijc.21043
164. Krahn M, Ritvo P, Irvine J, Tomlinson G, Bremner KE, Bezjak A, et al. Patient and community preferences for outcomes in prostate cancer: implications for clinical policy. Med Care 2003;41:153-64. http://dx.doi.org/10.1097/00005650-200301000-00017
165. Shimizu F, Fujino K, Ito YM, Fukuda T, Kawachi Y, Minowada S, et al. Factors associated with variation in utility scores among patients with prostate cancer. Value Health 2008;11:1190-3. http://dx.doi.org/10.1111/j.1524-4733.2008.00336.x
166. Volk RJ, Cantor SB, Cass AR, Spann SJ, Weller SC, Krahn MD. Preferences of husbands and wives for outcomes of prostate cancer screening and treatment. J Gen Intern Med 2004;19:339-48. http://dx.doi.org/10.1111/j.1525-1497.2004.30046.x
167. National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal. London: NICE; 2008. URL: www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf (accessed June 2012).
168. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005;293:2095-101. http://dx.doi.org/10.1001/jama.293.17.2095
169. Doo KW, Sung DJ, Park BJ, Kim MJ, Cho SB, Oh YW, et al. Detectability of low and intermediate or high risk prostate cancer with combined T2-weighted and diffusion-weighted MRI. Eur Radiol 2012;22:1812-19. http://dx.doi.org/10.1007/s00330-012-2430-5
170. Haider MA, Van Der Kwast TH, Tanguay J, Evans AJ, Hashmi AT, Lockwood G, et al. Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. AJR Am J Roentgenol 2007;189:323-8. http://dx.doi.org/10.2214/AJR.07.2211
171. Emberton M. MRI in diagnosing prostate cancer (ClinicalTrials. gov Identifier: NCT01292291). Bethesdaa, MD: US National Institutes of Health; 2012. URL: http://clinicaltrials.gov/ct2/show/NCT01292291?term=promis&rank=9 (accessed June 2012).
172. Leeflang MM, Deeks JJ, Gatsonis C, Bossuyt PM. Systematic reviews of diagnostic test accuracy. Ann Intern Med 2008;149:889-97.
173. Scattoni V, Zlotta A, Montironi R, Schulman C, Rigatti P, Montorsi F. Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature. Eur Urol 2007;52:1309-22. http://dx.doi.org/10.1016/j.eururo.2007.08.006
174. Scheenen TW, Futterer J. Prostate cancer localization with a multiparametric magnetic resonance (MR) approach (ClinicalTrials. gov Identifier: NCT01138527). Bethesdaa, MD: US National Institutes of Health; 2012. URL: http://clinicaltrials.gov/ct2/show/NCT01138527 (accessed June 2012).
175. Engelbrecht MR, Jager GJ, Laheij RJ, Verbeek AL, van Lier HJ, Barentsz JO. Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis. Eur Radiol 2002;12:2294-302.
176. Lawrentschuk N, Fleshner N. The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels. BJU Int 2009;103:730-3. http://dx.doi.org/10.1111/j.1464-410X.2008.08205.x
177. Wang P, Guo YM, Liu M, Qiang YQ, Guo XJ, Zhang YL, et al. A meta-analysis of the accuracy of prostate cancer studies which use magnetic resonance spectroscopy as a diagnostic tool. Kor J Radiol 2008;9:432-8. http://dx.doi.org/10.3348/kjr.2008.9.5.432
178. Costouros NG, Coakley FV, Westphalen AC, Qayyum A, Yeh BM, Joe BN, et al. Diagnosis of prostate cancer in patients with an elevated prostate-specific antigen level: role of endorectal MRI and MR spectroscopic imaging. AJR Am J Roentgenol 2007;188:812-16. http://dx.doi.org/10.2214/AJR.06.0165
179. Perrotti M, Han KR, Epstein RE, Kennedy EC, Rabbani F, Badani K, et al. Prospective evaluation of endorectal magnetic resonance imaging to detect tumor foci in men with prior negative prostatic biopsy: a pilot study. J Urol 1999;162:1314-17. http://dx.doi.org/10.1016/S0022-5347(05)68275-4
180. Mueller-Lisse UG, Vigneron DB, Hricak H, Swanson MG, Carroll PR, Bessette A, et al. Localized prostate cancer: effect of hormone deprivation therapy measured by using combined threedimensional 1H MR spectroscopy and MR imaging: clinicopathologic case-controlled study. Radiology 2001;221:380-90. http://dx.doi.org/10.1148/radiol.2211001582
181. Yu KK, Scheidler J, Hricak H, Vigneron DB, Zaloudek CJ, Males RG, et al. Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology 1999;213:481-8.
182. Rorden C, Brett M. Stereotaxic display of brain lesions. Behav Neurol 2000;12:191-200.